Skip to main content
AT

Avisi Technologies

Avisi Technologies is developing VisiPlate, a nanotechnology-enabled aqueous shunt designed to lower intraocular pressure in patients with open-angle glaucoma. This investigational implant addresses the risk of irreversible blindness by providing a minimally invasive solution that enhances aqueous drainage through a network of microchannels.

Redwood City, United StatesFounded 2017213K+ followers
Updated 4 months ago

Funding

$20.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Funding rounds are not available yet.

Founders

Product

Problem

Glaucoma, a leading cause of irreversible blindness, often results from elevated intraocular pressure (IOP) due to inadequate drainage of aqueous humor. Existing treatments can slow disease progression but cannot reverse vision loss, and current surgical options carry risks of scarring and foreign body response.

Solution

Avisi Technologies is developing VisiPlate, a next-generation aqueous shunt that aims to lower IOP in patients with open-angle glaucoma. The investigational implant utilizes a network of microchannels to enhance aqueous drainage from the anterior chamber, providing a minimally invasive solution. VisiPlate is constructed from an ultrathin, nonfibrotic material designed to minimize foreign body response and reduce the risk of scarring, a common cause of failure in existing glaucoma treatments. The VisiPlate procedure is designed for outpatient settings, intending to control IOP and improve patients’ quality of life.

Target Audience

The primary target audience includes glaucoma surgeons and patients with open-angle glaucoma requiring IOP reduction.

Features

  • Multichannel design to control aqueous drainage from the anterior chamber
  • Ultrathin material (several times thinner than a human hair) for greater patient comfort and aesthetics
  • Innovative composition of alumina and Parylene-C to minimize foreign body response and reduce the risk of scarring
  • Fabrication using MEMS (Micro-Electro-Mechanical Systems) manufacturing and advanced micro-fabrication techniques
This profile is AI-generated and may contain inaccuracies.